From: Safety of 100 µg venom immunotherapy rush protocols in children compared to adults
Patient no. | 1 | 2 | 3 | 4 | 5 |
---|---|---|---|---|---|
History | |||||
Age (years) | 7 | 7 | 7 | 15 | 17 |
Sex | F | M | M | F | M |
Causative venom | Bee | Vespula | Vespula | Vespula | Bee |
Severity of anaphylaxis at index sting (grade) | II | II | II | III | II |
Relevant comorbidities | None | None | Asthma | None | None |
Concurrent medication | None | None | Yesa | None | None |
VIT-induced anaphylaxis | |||||
Severity (grade) | II | I | I | I | I |
Symptoms | |||||
Urticaria/angioedema | + | + | + | + | + |
Respiratory | + | − | − | − | − |
Gastrointestinal | + | − | − | − | − |
Cardiovascular | − | − | − | − | − |
Injection protocol | 3 days | 3 days | 3 days | 3 days | 5 days |
Venom dose prior to reaction (µg) | 50 | 40 | 50 | 40 | 8 |
Time interval to injection (minutes) | 15 | 60 | 120 | 25 | 60 |
Treatment | |||||
Antihistamine | i.v. | Oral | i.v. | i.v. | Oral |
Steroid | i.v. | − | − | − | − |
Epinephrine | − | − | − | − | − |
Inhalative beta2-adrenergic agonist | + | − | − | − | − |